NRX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.54 USD | +0.57% |
|
+16.45% | -23.04% |
| May. 14 | Transcript : NRx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
| May. 06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 36.89M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M | Net income 2025 * | -21M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.62
x | P/E ratio 2025 * |
-1.69
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on NRx Pharmaceuticals, Inc.
More press releases
More news
| 1 day | +0.57% | ||
| 1 week | +16.45% | ||
| Current month | +37.21% | ||
| 1 month | -15.31% | ||
| 3 months | -24.81% | ||
| 6 months | +14.45% | ||
| Current year | -23.04% |
1 week
2.87
3.99
1 month
1.903.99
Current year
1.907.33
1 year
1.9012.00
3 years
1.90488.00
5 years
1.90769.90
10 years
1.90769.90
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 23-09-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Janet Rehnquist
BRD | Director/Board Member | - | Dec. 26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 3.54 | +0.57% | 203,700 |
| 24-05-16 | 3.52 | +8.98% | 920,229 |
| 24-05-15 | 3.23 | +1.57% | 182,108 |
| 24-05-14 | 3.18 | +6.35% | 271,403 |
| 24-05-13 | 2.99 | -1.64% | 170,661 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.54
USD
Average target price
35
USD
Spread / Average Target
+888.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.04% | 36.89M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- BRPA Stock
